Additional Information

Description

Juluca (dolutegravir and rilpivirine) 50 mg/25 mg tablets are a fixed-dose combination for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults. The tablet combines two antiretroviral agents: dolutegravir, an integrase strand transfer inhibitor (INSTI), and rilpivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI). Both medications work together to inhibit critical steps in the HIV replication cycle, ultimately reducing the viral load and helping to achieve and maintain virologic suppression.

Dolutegravir inhibits the HIV integrase enzyme, preventing the integration of viral DNA into the host cell’s genome, while rilpivirine inhibits reverse transcriptase, blocking the conversion of viral RNA into DNA. The combination of these two agents offers potent antiretroviral activity with a simplified, once-daily regimen for patients who are virologically suppressed with no history of treatment failure or resistance to either component.

Each tablet is administered orally once daily with or without food. The fixed-dose combination provides convenience and ease of use compared to separate medications, supporting improved adherence to treatment. Common side effects include headache, insomnia, and gastrointestinal disturbances, while serious side effects may include hypersensitivity reactions and liver abnormalities.